Slate Path Capital’s Standard BioTools LAB Stock Holding History

Slate Path Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Hold	1,615,000	–	–	0.02%	43
2025 Q4	$2.07M	Hold	1,615,000	–	–	0.03%	50
2025 Q3	$2.1M	Hold	1,615,000	–	–	0.03%	50
2025 Q2	$1.94M	Hold	1,615,000	–	–	0.03%	42
2025 Q1	$1.74M	Hold	1,615,000	–	–	0.03%	49
2024 Q4	$2.83M	Hold	1,615,000	–	–	0.05%	50
2024 Q3	$3.12M	Hold	1,615,000	–	–	0.05%	61
2024 Q2	$2.86M	Hold	1,615,000	–	–	0.05%	56
2024 Q1	$4.38M	Buy	+1,615,000	New	+$3.9M	0.09%	52

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Slate Path Capital's LAB Position: Q1 2026 in Review

Slate Path Capital held its Standard BioTools (LAB) position steady in Q1 2026 at 1,615,000 shares worth $1.48M. The position accounts for 0.02% of the portfolio, ranked #43.

Slate Path Capital first reported a position in LAB in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.38M in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Slate Path Capital held 1,615,000 shares of Standard BioTools worth $1.48M as of Q1 2026.
Slate Path Capital left its Standard BioTools share count unchanged in Q1 2026.
Standard BioTools made up 0.02% of Slate Path Capital's portfolio in Q1 2026, its #43 holding.
Slate Path Capital first reported a position in Standard BioTools in Q1 2024 and has held it in 9 quarters since.
Slate Path Capital's Standard BioTools position peaked at $4.38M in Q1 2024.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Slate Path Capital's 13F filing for Q1 2026, filed 15 May 2026.